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related increases in glomerular production of NOx were mark-Tandem antifibrotic actions of L-arginine supplementation and
edly reduced by low protein. Combined therapy resulted inlow protein diet during the repair phase of experimental glo-
small, but statistically significant decreases in most measuresmerulonephritis.
of disease.Background. Based upon the central role transforming
Conclusions. l-arginine supplementation reduces fibroticgrowth factor-beta (TGF-b) overexpression appears to play in
disease in ATS-induced glomerulonephritis if started after dis-renal fibrotic diseases, we have recently advocated reduction
ease induction. The absence of evidence for increased NOof TGF-b as a therapeutic target. As part of efforts to determine
production related to l-arginine supplementation suggests thatthe strength of this approach, we have undertaken studies to
l-arginine is acting here through different pathways from thosequantitate the effects of currently used and promising therapies
demonstrated in hypertensive models of disease. The data sup-in terms of their potential to reduce markers of disease in anti-
thymocyte-serum (ATS)-glomerulonephritis in the rat. Here port the ideas that TGF-b reduction is a valid therapeutic target
we assess the therapeutic effect of l-arginine supplementation, and that quantitation of TGF-b reduction is a useful approach
which has been shown to reduce fibrosis in a number of hyper- for comparing antifibrotic drug candidates.
tensive models, given alone or in combination with low protein
diet and started 24 hours after disease induction.
Methods. Glomerulonephritis was induced by intravenous
Tissue fibrosis results from the accumulation of exces-injection of OX-7 monoclonal antibody into 200 g Sprague-
sive amounts of pathological extracellular matrix [1]. ItDawley rats. Twenty-four hours later animals were placed in
groups that were either untreated, treated with 1% l-arginine is now clear that overexpression of the cytokine trans-
in drinking water or 6% protein diets or both. On the fifth day forming growth factor-b (TGF-b) occurs in essentially all
of disease 24-hour urine specimens were collected and systemic
fibrotic diseases [1]. A large number of stimuli relevant toblood pressure was measured. On the sixth day rats were anes-
renal fibrosis have been shown to cause increased TGF-bthetized. Kidneys were perfused, tissue was taken for PAS
staining and glomeruli were isolated. Aliquots of glomeruli expression [reviewed in 2, 3]. It is now conceivable that
were used for RNA preparation and for culture to determine one or more of these factors, or as yet unidentified fac-
72-hour production of TGF-b, fibronectin and plasminogen tors, lead to increased TGF-b in most, if not all, renal
activator-type 1 (PAI-1), which were assayed by ELISA on
fibrotic diseases. This increased TGF-b directly leadsculture supernatants. Measures of nitrate and nitrite (NOx)
to increased pathological matrix accumulation by: (1)production included plasma NOx, urinary NOx and glomerular
production of NOx in culture. increasing synthesis of matrix proteins, (2) decreasing
Results. All disease measures except proteinuria and includ- degradation of matrix proteins, and (3) increasing syn-
ing matrix accumulation, TGF-b, fibronectin and PAI-1 produc- thesis and expression on the cell membrane of a grouption and mRNA expression for TGF-b, fibronectin and PAI-1
of cell-matrix receptors called integrins [reviewed in 1].were significantly and similarly reduced by about 50% in groups
While the interconnections between TGF-b and fac-treated with l-arginine or with low protein diet. Proteinuria
was reduced in low protein treated but not in l-arginine supple- tors that increase its expression are currently a very ac-
mented rats. Neither systemic blood pressure nor measures of tive area of research in many laboratories, including our
NO synthesis showed differences between groups that could be own, we have recently advocated an approach to therapyattributed to l-arginine supplementation. In contrast, disease-
of renal fibrosis which targets reduction of TGF-b, re-
gardless of the mechanisms involved in its overexpres-
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important process might be expected to have many action are poorly understood, to test for additive effects
on disease severity.“back-up” pathways, and indeed there is evidence to
l-arginine supplementation is a promising therapy insuggest that this is the case [3]. It may be argued, there-
that it has been shown to reduce histological signs offore, that unraveling the interconnections between these
kidney fibrosis in a number of disease models [7–14] andpathways will take many years of research, while thera-
has been advocated for human trials (abstract, Ciancia-peutic targeting of TGF-b overexpression is feasible now.
ruso et al, J Am Soc Nephrol 7:1316A, 1996). l-arginineThere is also ample evidence that the degree of TGF-b
supplementation is also a therapeutic approach where theoverexpression is directly related to the speed with which
mechanism of action appears complex [15]. l-arginine is apathological matrix accumulates. For example, in the
semi-essential amino acid and a precursor for endogenousstreptozotocin model of diabetes where matrix accumu-
production of nitric oxide (NO) [reviewed in 16]. NOlates slowly, TGF-b overexpression increases slowly over
normally produced in small amounts by constitutively ex-many weeks [4]. In anti-thymocyte-serum (ATS)-induced
pressed NO synthases in endothelial cells (eNOS) is anglomerulonephritis, which shows considerable matrix ac-
important vasodilator, as demonstrated by studies show-cumulation in six days, TGF-b overexpression occurs
ing that blockade of NO production with the NOS blockerrapidly and TGF-b levels are many-fold higher than nor-
l-monomethylarginine (l-NAME) leads to increased his-mal (this study and [5]). In a series of studies of immuno-
tological evidence of disease [17]. Dietary l-arginine sup-histochemical staining of TGF-b in human renal tissue,
plementation is believed to increase eNOS synthesis ofTGF-b overexpression was greatest in HIV associated
NO and thereby to limit hypertensive injury to the kid-nephropathy, a disease that rapidly progresses to renal
ney. Although it is indisputable that complete blockadefailure [6].
of normal endogenous production of NO by endothelialBased on these findings, we have undertaken a series
cells is harmful, it is not clear that l-arginine supplemen-of experiments to evaluate current and promising thera-
tation enhances this production directly through increasedpies in terms of their ability to reduce pathological over-
availability of substrate. For example, the blood pressureexpression of TGF-b. We have chosen to use the ATS
lowering effect of l-arginine infusion is largely mediatedmodel of glomerulonephritis because it is rapid and
through insulin release rather than through increasedhighly reproducible and the measures of disease we em-
substrate availability for endothelial NO production [18].ploy show large differences between normal and dis-
l-arginine is also a substrate for agmatine, a compoundeased glomeruli, a fact that allows small differences in
whose role in renal disease is just beginning to emergetherapeutic efficacy to be seen. In addition, this model
[reviewed in 19]. Thus, it appears very possible thatof disease has a distinct “injury” phase during which the
the therapeutic action of l-arginine supplementation is
injected antibody causes complement-mediated lysis of
through pathways other than simply enhanced vasodila-
a portion of the glomerular mesangial cells and a distinct tory NO production by endothelial cells.
“repair” phase, where mesangial cell proliferation, TGF-b Another complicating factor is that tissue injury is
overexpression and matrix deposition occur. dependent upon generation of cytotoxic quantities of
Using this model, and studying the repair phase of NO through induction of another isoform of nitric oxide
disease only by starting therapy 24 hours after disease synthase, inducible NOS (iNOS) in a number of models
induction, we have recently shown that a greater thera- of disease, including lupus nephritis and kidney ischemia-
peutic effect is seen with the angiotensin converting en- reperfusion [20–22]. Increased expression of iNOS in
zyme (ACE) inhibitor, enalapril or the angiotensin re- patients with IgA nephropathy and renal transplant re-
ceptor antagonist, losartan, if doses are higher than those jection has been shown (abstract, Ikegaya et al, J Am
shown to normalize systemic blood pressure in hyperten- Soc Nephrol 7:1563A, 1996) [23]. Renal transplant rejec-
sive rats [5]. Combining these drugs gave no additional tion is also paralleled by increased NO in the urine [24].
therapeutic effect [5]. A preliminary study showed that Inducible NOS induction and NO generation are also
when maximally effective doses of enalapril are com- involved in the injury phase of ATS-induced disease
bined with a 6% protein diet, a small additive effect was where restriction of l-arginine intake before disease in-
seen (Note added in proof). While these studies give duction and pretreatment with the NOS blocker l-NAME
clues as to the mechanisms by which these treatments significantly reduce cell lysis [20]. In contrast, dietary
act, they are designed primarily to give information as supplementation of l-arginine, given only during the in-
to their therapeutic potential with less emphasis on jury phase of disease, increases injury and the fibrotic
mechanisms. The study presented here looks at the abil- response that follows [25].
ity of l-arginine supplementation, started 24 hours after Dietary manipulations of l-arginine therefore exem-
disease induction, to reduce TGF-b and other disease plify the mechanistic complexity of promising therapies
markers. l-arginine supplementation was also combined and help to make the argument that empirical data on
therapeutic efficacy have value.with low protein diet, a therapy whose mechanisms of
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METHODS the rats (N 5 8 per group) were assigned to the following
dietary modifications: (1) normal control animals on aMaterials
normal protein diet; (2) OX-7-injected animals (GN) onIf not otherwise indicated, materials, chemicals or cul-
a normal protein diet (GN-NP); (3) GN rats on a normalture media were purchased from Sigma Chemical Co.
protein diet with 1% l-arginine in the drinking water(St. Louis, MO, USA).
(GN-NP 1 Arg); (4) GN rats on a low protein diet (6%
casein, Teklad No. 86 551) (GN-LP); and (5) GN ratsAnimals
on a low protein diet with 1% l-arginine in the drinkingThe studies were performed in male Sprague-Dawley
water (GN-LP 1 Arg). The normal protein and the low(SD) rats (200 to 270 g) obtained from Sasco (Omaha,
protein diet were identical in fat and mineral content.NB, USA). Glomerulonephritis was induced by tail vein
The low protein diet was made isocaloric (14.6 J/g) byinjection of the monoclonal anti-Thy 1.1 antibody OX-7
addition of sucrose.(1.5 mg/kg). OX-7 binds to a Thy 1-like epitope on the
Five days after disease induction, systolic blood pres-surface of mesangial cells and causes complement-
sure was measured in the conscious state by tail cuff [27].dependent cell lysis [26]. Normal control animals were
The rats were housed in metabolic cages and urine wasinjected with the same volume of phosphate-buffered
collected for 24 hours. Six days after injection, the ani-saline (PBS). Body weight, food and water intake were
mals were anesthetized with ether. Following a midlinemonitored individually at the beginning and end of each
abdominal incision, heparinized blood was drawn fromexperiment.
the lower abdominal aorta. The blood was immediately
centrifuged and plasma was frozen at 2708C until analy-OX-7 production
sis of plasma l-arginine and nitrite 1 nitrate (NOx) lev-The monoclonal antibody was produced in the ascitic
els. The kidneys were subsequently perfused with 30 mLfluid of primed adult female BALB/c mice (Charles
ice-cold PBS and harvested. Cortical tissue was fixed inRiver, Wilmington, MA, USA). The hybridoma was ob-
10% neutral buffered formalin for histological examina-tained from American Type Culture Collection (Rock-
tion. Glomeruli from individual rats were isolated by aville, MD, USA) and the cells were grown in RPMI 1640
graded sieving technique (150, 125, 106 and 75 mm mesh(Gibco BRL, Long Island, NY, USA) supplemented with
metal sieves) as described previously [28].10% fetal calf serum (FCS), 100 U/mL penicillin, 100
An aliquot of glomeruli was resuspended in DMEMmg/mL streptomycin and 25 mmol/L HEPES buffer at
supplemented with 0.1 U/mL insulin, 100 U/mL penicil-378C/5% CO2 and passaged at confluence. The mice were
lin, 100 mg/mL streptomycin and 25 mmol/L HEPESprimed with two intraperitoneal injections of 0.5 ml pris-
buffer. After 72 hours of incubation at 378C/5% CO2 thetane (2,6,10,14-tetramethyldecanoic acid) one week apart.
supernatant was harvested and stored at 2708C untilThree days after the second pristane administration, the
analysis of glomerular TGF-b1, fibronectin and PAI-1hybridoma cells were spun at 3000 g for five minutes
and NO production. Preliminary studies have indicatedand resuspended in PBS (pH 7.4). Approximately 1 to 2
that production of TGF-b1, fibronectin, PAI-1 and NOmillion cells in 0.5 ml PBS were injected intraperitoneally
by isolated glomeruli are constant for 72 hours of cultureper mouse. When the mice developed noticeable ascites,
(unpublished observations). The 72 hour harvest of cul-they were anesthetized with ether and the ascitic fluid
ture supernatant was chosen based on these data and onwas collected.
the fact that quantities of these molecules are sufficientTo purify the IgG fraction, ascitic fluid was combined
at this time to obtain accurate ELISA measurements.with 2/10 volumes 1.0 mol/L Tris (pH 8.0) and applied
The remaining glomeruli were lyzed in Trizole Reagentto a pre-equilibrated Protein G column (Pierce, Rock-
and homogenized with three short bursts of a tissue ho-ford, IL, USA). The antibody fraction was eluted with
mogenizer. After five minutes of incubation at room100 mmol/L glycine (pH 3.0) and promptly neutralized
temperature, the samples were stored at 2708C untilwith Tris (pH 9.0). After extensive dialysis against PBS
RNA isolation.(pH 7.4) the antibody concentration was adjusted to 1
mg/mL by reading the adsorbance at 280 nm and stored
Light microscopyat 2708C until use.
Microscopic examinations were performed in a blinded
Experimental design fashion on 3 mm sections of paraffin-embedded tissues
stained with periodic acid Schiff (PAS). Glomerular ma-For at least three days before induction of glomerulo-
trix expansion was evaluated in 30 glomeruli from eachnephritis, animals were fed a normal protein diet (22%
rat by scoring the percentage of mesangial matrix occu-casein, Teklad No. 86 550; Teklad Premier Laboratory
pying each glomerulus where: 0 5 0%, 1 5 25%, 2 5Diets, Madison, WI, USA) with an l-arginine content of
0.85%. Twenty-four hours after OX-7 or PBS-injection, 50%, 3 5 75% and 4 5 100%.
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Fig. 1. (A) Mean L-arginine intake over the
course of the experiment. (B) Urinary protein
excretion measured on urine collected for the
24 hours preceding sacrifice. After induction of
ATS glomerulonephritis (GN), rats were fed a
normal protein diet (NP, 22% casein) or a low
protein diet (LP, 6% casein). In some groups
the drinking water supplemented 1% l-arginine
(1Arg).
TGF-b1, fibronectin and PAI-1 ELISAs reaction after nitrate reductase treatment [34]. Briefly,
samples were diluted in PBS and incubated at roomTGF-b1 production of cultured glomeruli was mea-
temperature in the presence of 0.05 mmol/L NADPHsured after acid-activation using a commercially avail-
and 0.05 Units nitrate reductase (Boehringer Mannheimable kit (Quantikinee; R&D Systems, Minneapolis, MN,
Biochemicals). After 45 minutes incubation at room tem-USA) according to the manufacturer’s instructions. Fi-
perature, proteins were precipitated with 70% zinc sul-bronectin and PAI-1 synthesis were measured with mod-
fate solution and samples were centrifuged at 14,000 gified inhibitory enzyme-linked immunosorbant assays
(ELISA) according to published methods [29]. Three for five minutes. One hundred microliters of sample was
samples from each rat were analyzed. then mixed with 100 mL Griess reagent (0.05% N-(1-
naphthyl) ethylene diamine dihydrochloride, 0.5% sulfa-
RNA preparation and Northern hybridization nilamide in 45% glacial acetic acid) in 96 well plates.
Total RNA was extracted by a guanidinium isothiocy- After 10 minutes incubation in the dark, adsorbance was
anate method using Trizole Reagent according to the read at 546 nm in an automated plate reader (Ther-
manufacturer’s instructions. Pooled glomeruli were used momax: Molecular Devices, Menlo Park, CA, USA).
for subsequent RNA extraction. For Northern analysis, Standard samples were prepared with sodium nitrate and
RNA was denatured and fractionated by electrophoresis were also nitrate reductase-treated.
through a 1.8% agarose gel (20 mg/lane) and transferred
For measurement of the glomerular NO production,to a Hybond nylon membrane (Amersham Corp., UK).
100 mL of samples were mixed with 100 mL of GriessNucleic acids were immobilized by UV irradiation. Mem-
reagent. Standard probes were prepared using sodiumbranes were prehybridized with 50% formamide, 10%
nitrite.Denhardt’s solution, 0.1% SDS, 5 3 SSC and 200 mg/ml
denatured salmon sperm DNA and hybridized with DNA
L-arginine level analysisprobes labeled with 32P-dCTP by random oligonucleotide
Plasma l-arginine levels were determined by an auto-priming (Boehringer Mannheim Biochemicals, India-
mated amino acid analyzer [35].napolis, IN, USA). The blots were washed in 2 3 SSC,
0.1% SDS at room temperature for 15 minutes and in
Statistical analysis0.1 3 SSC, 0.1% SDS at 558C for 30 minutes. DNA
probes used were: (1) rat glyceraldehyde-3-phosphate Data are expressed as mean 6 SEM. Statistical analy-
dehydrogenase (GAPDH) cDNA (a gift from Drs. P. sis between the groups was performed by ANOVA and
Kondaiah and M.B. Sporn) [30], (2) TGF-b1 cDNA subsequent t-testing with Bonferroni correction for mul-
(kindly provided from Dr. D.L. Moses) [31], (3) fibro- tiple comparison. A P value , 0.05 was considered sig-
nectin-EDA cDNA (a generous gift from Dr. R.O. nificant.
Hynes) [32], (4) PAI-1 cDNA (kindly provided by Dr.
T.D. Gelehrter) [33]. Three blots per probe were per-
RESULTSformed.
Body weight, food and water intake andProteinuria
L-arginine intake
Proteinuria was measured using the Bradford method
There were no significant differences between theand is expressed as mg protein/24 hours [28].
groups in body weight or food and water intake during
NOx measurements the experiment. Systemic blood pressures also did not vary
and were as follows: mean 6 SEM; normal control, 111 6Nitrite and nitrate are stable endproducts of NO and
8 mm Hg; GN-NP, 110 6 6 mm Hg; GN-NP 1 Arg, 113 6served as indicators of NO synthesis. Plasma and urinary
NO2/NO3 (NOx) levels were measured by the Griess 3 mm Hg; GN-LP, 114 6 56 mm Hg; GN-LP 1 Arg,
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Fig. 2. (A) Glomerular matrix accumulation
six days after induction of ATS glomerulone-
phritis (GN). Animals were fed a normal protein
diet (NP, 22% casein) or a low protein diet (LP,
6% casein). In some groups the drinking water
supplemented 1% l-arginine (1Arg). B, C and
D show the glomerular production of TGF-b1,
fibronectin and PAI-1 in supernatants of cul-
tured glomeruli, respectively. *P , 0.01 versus
GN-NP, #P , 0.05 versus GN-NP 1 ARG and
GN-LP.
111 6 7 mm Hg. Figure 1A shows l-arginine intake. mentation of the drinking water with 1% l-arginine and
dietary protein restriction (normal control, 2.58 6 0.04;Because l-arginine intake was determined by weighing
food, the data are estimates and measures of variability GN-NP 1 Arg, 2.13 6 0.06; GN-LP, 2.09 6 0.04).
Glomerular production of TGF-b1, fibronectin andare not given. l-arginine feeding increased l-arginine in-
take 3.6-fold above normal in rats on a normal protein PAI-1. Glomerular TGF-b1 protein production in vitro
diet and 7.7-fold above normal in rats on a low protein was increased by 8.9-fold in untreated nephritic rats
diet. Compared to rats fed a normal protein diet, l- (GN-NP) compared to the normal controls (Fig. 2B).
arginine intake was 3.5-fold lower in the low protein diet Glomerular fibronectin synthesis was elevated 15-fold
group drinking tap water only (Fig. 1A). and glomerular PAI-1 synthesis 25-fold (Fig. 2 C, D,
respectively). A significant reduction in glomerular pro-
Proteinuria duction of TGF-b, fibronectin and PAI-1 was seen in
Proteinuria data are shown in Figure 1B. Proteinuria the rats treated with either l-arginine supplementation
was significantly increased in nephritic animals fed a or low protein diet (Fig. 2 B–D). Compared to the disease
normal protein diet whether they were supplementated control animals, l-arginine administration reduced glo-
with l-arginine or not (normal control, 16 6 2 mg/24 h; merular production of TGF-b1 by 40%, fibronectin by
GN-NP, 52 6 10 mg/24 h; GN-NP 1 Arg, 60 6 12 mg/24 h, 41% and PAI-1 by 50% (GN-NP 1 Arg). Low protein
P , 0.01). Proteinuria in nephritic rats fed a low protein feeding decreased production of TGF-b1, fibronectin
diet was significantly reduced compared to nephritic rats and PAI-1 protein by 44%, 50% and 60% (GN-LP). The
fed a normal protein diet, again whether they were supple- extent of reduction in pathological overexpression of
mented with l-arginine or not (GN-NP, 52 6 10 mg/24 h, TGF-b, fibronectin and PAI-1 did not differ between
GN-LP, 13 6 5 mg/24 h; GN-LP 1 Arg, 10 6 4 mg/24 h; the two single therapies, l-arginine supplementation and
P , 0.01). In addition, proteinuria was slightly, but not low protein diet (P . 0.05).
significantly reduced in nephritic rats fed low protein Glomerular expression of mRNAs for TGF-b1, fibro-
compared to normal rats (Fig. 1B). Thus, in nephritic nectin and PAI-1. A representative Northern blot is shown
rats, proteinuria followed protein intake and not l-argi- in Figure 3A. Expression of mRNA, quantitated by laser
nine intake. densitometry and averaged for three blots, is shown
graphically in Figures 3B–D. Disease alone (GN-NP) re-
Effect of L-arginine supplementation and low protein sulted in increases of 3.7-, 34- and 62-fold for TGF-b1,
feeding on markers of fibrotic disease 6 days after fibronectin and PAI-1 mRNAs (Fig. 3 B–D, respec-
disease induction tively). A significant reduction in mRNA expression was
seen in the rats treated with either l-arginine supplemen-Histological examination. As shown graphically in
Figure 2A, glomerular matrix accumulation was signifi- tation (GN-NP 1 Arg) or low protein diet (GN-LP)
(Fig. 2A–D and 3A–D). Compared to the disease controlcantly and to a similar extent reduced by both supple-
Peters et al: l-arginine and low protein diet in GN 997
Fig. 3. (A) A representative Northern blot showing glomerular mRNA expression of GAPDH, TGF-b1, fibronectin and PAI-1 harvested six
days after induction of glomerulonephritis (GN). After correction for quantities of mRNA for GAPDH, mRNA levels are shown graphically for
(B) TGF-b1, (C) fibronectin and (D) PAI-1. Molecular size markers are shown on the right. *P , 0.05 versus GN-NP.
animals (GN-NP), l-arginine administration reduced and glomerular production of TGF-b, fibronectin and
PAI-1 was seen with combined therapy. TGF-b overpro-glomerular mRNA of TGF-b1 by 34%, fibronectin by
62% and PAI-1 by 59% (GN-NP 1 Arg; Fig. 3B–D). duction was reduced a total of 69%, fibronectin overpro-
duction by 71% and PAI-1 overproduction by 79% (Fig.Low protein feeding decreased mRNA expression of
TGF-b1, fibronectin and PAI-1 by 38%, 64% and 58%, 2). The reductions in TGF-b1, fibronectin and PAI-1
mRNA levels seen with dual therapy were 52%, 81%respectively (GN-LP; Fig. 3B–D). Again, single therapy
resulted in very similar reductions in mRNA expression. and 77%, respectively (Fig. 3).
Effects of l-arginine supplementation and low proteinAdditive effects of l-arginine supplementation and low
protein diet. Using as powerful measures of disease se- diet on plasma l-arginine levels. Arterial l-arginine lev-
els are shown in Figure 4A. Disease itself (GN-NP) re-verity matrix score, glomerular production of TGF-b,
fibronectin and PAI-1 and Northern blotting of RNA to sulted in significantly decreased arterial l-arginine levels
whether rats were fed normal (NP) or low (LP) proteinquantitate the mRNAs for these proteins, a significantly
enhanced therapeutic effect was seen when both thera- diet, suggesting either increased utilization of l-arginine
during disease or decreased synthesis by proximal tubu-pies were combined (Figs. 2 and 3). Dual therapy re-
duced all measures of disease, except proteinuria (Fig. lar cells that are the main site of in vivo l-arginine pro-
duction [36]. l-arginine supplementation corrected this1B), to a greater extent than either therapy alone. As
shown in Figure 2, a significant reduction in matrix score disease-induced decrease and gave plasma values 338%
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Fig. 4. Arterial L-arginine concentrations (A) and NOx levels (B) six days after disease induction. Urinary NOx excretion over the 24 hours
before sacrifice and glomerular NOx production in culture over 72 hours after harvest are shown in (C) and (D), respectively. *P , 0.05 versus
normal, #P , 0.05 versus normal, GN-NP and GN-NP 1 Arg.
and 226% above normal levels in diseased animals on tion of NOx (Fig. 4C). Feeding nephritic rats a low pro-
tein diet, whether supplemented with l-arginine or not,normal and low protein diet, respectively.
lead to a dramatic decrease in urinary NOx excretion
Effects of L-arginine supplementation and low protein (Fig. 4C). The finding that plasma NOx levels are not
diet on nitrite 1 nitrate (NOx) content of plasma and reduced by low protein feeding (Fig. 4B) suggests that
urine and NOx production by glomeruli in culture the decrease in urinary NOx (Fig. 4C) is not due to
systemic decreases in NO production, but may be dueNOx was measured in three types of samples, plasma
(Fig. 4B), urine (Fig. 4C) and supernatant from glomeruli to decreased production by the nephron of nephritic rats
on a low protein diet. However, glomerular productioncultured for 72 hours (Fig. 4D). A striking feature of the
data shown in these figures is that the level of NOx in of NOx in these rats is significantly elevated compared
to normal glomeruli (Fig. 4D). Thus, it is likely the reduc-no case reflected the presence of absence of l-arginine
supplementation. Where there were differences between tion of urinary excretion of NOx in nephritic animals
fed a low protein diet is due to decreased production bytreatment groups, they followed protein intake. Thus,
urinary excretion of NOx was normal in nephritic ani- proximal tubular cells.
Also shown in Figure 4D are data indicating that ne-mals on a normal protein diet and significantly reduced
in both groups of animals on a low protein diet. Arterial phritic rat glomeruli on a normal protein diet, whether
supplemented with l-arginine or not, produce signifi-NOx levels were the same in all groups, suggesting that
l-arginine supplementation does not cause large, sys- cantly more NOx than normal control glomeruli, a differ-
ence that is not reflected in urinary NOx (Fig. 4C). Basedtemic changes in NO production (Fig. 4B). Urinary NOx
excretion was also very similar in normal, untreated ne- on the data in Figure 4, it appears that: (1) plasma
l-arginine levels are reduced by disease itself both inphritic and nephritic rats on normal protein diets with
l-arginine supplementation, suggesting that l-arginine the presence of normal and high l-arginine intake. (2)
Neither the presence nor absence of ATS-induced glo-supplementation alone does not increase urinary excre-
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merulonephritis or large differences in l-arginine intake All disease measures except proteinuria were signifi-
cantly reduced by l-arginine supplementation, confirming(Fig. 1), plasma l-arginine levels or protein intake pro-
duce detectable changes in plasma NOx content. (3) Nei- other studies, mostly in hypertensive models of disease,
showing that this therapeutic approach is potentially ofther plasma l-arginine levels nor disease state are clearly
reflected in urinary NOx content, but appear to be benefit to humans. The fact that proteinuria was not
reduced by l-arginine supplementation, while all othergreatly affected by low protein intake. (4) Glomerular
NO production is about threefold increased by ATS-GN measures of disease were decreased is interesting, al-
though the reasons why proteinuria did not follow fi-and is not altered by l-arginine supplementation but is
greatly reduced by low protein intake. (5) Differences brotic disease severity are unclear. It may be relevant
to point out that proteinuria in antithymocyte serum-in glomerular NOx synthesis are not clearly reflected by
urinary NOx content. These data reveal a clear effect of induced glomerulonephritis does not always follow the
severity of the fibrotic response. Some rat strains do notlow protein intake on NO synthesis by the nephron, an
interesting, and we believe, a new link between NO and show proteinuria as part of this disease [41]. In addition,
using the same rat strain, the degree of proteinuria varieslow protein intake.
with the antibody or antiserum used to produce disease
far more than the fibrotic response (unpublished obser-
DISCUSSION
vation). Nonetheless, in these Sprague-Dawley rats with
The present study demonstrates the power of the mea- OX-7 antibody, proteinuria at day 6 usually follows se-
sures employed to compare different therapies side-by- verity of fibrosis. Therefore, the finding that proteinuria
side. For reasons covered in the Introduction, TGF-b is not reduced by l-arginine supplementation is of in-
was used as a key marker of disease. The other major terest.
markers were fibronectin and PAI-1; both strongly in- Although this study provides another example of the
duced by TGF-b1 in vitro [37, 38]. Fibronectin expression antifibrotic effects of dietary l-arginine supplementation,
was used as a sensitive marker of extracellular matrix it remains unclear which metabolite(s) or pathway(s) me-
synthesis. The protease inhibitor PAI-1 was used as an diate this effect. Studies using subtotal nephrectomy, ure-
indicator of the activity of matrix degrading systems. The teral obstruction and salt sensitive Dahl/Rapp rats have
importance of PAI-1 in matrix breakdown has recently suggested that l-arginine supplementation increases en-
been shown in a study of mesangial cells in culture [39] as dothelial NO production, thereby limiting hypertensive
well as in an in vivo model of lung fibrosis [40]. Following renal tissue damage [8, 11, 13]. This view is supported
bleomycin administration, mice with genetic PAI-1 over- by evidence for increased NO synthesis in these models
expression showed markedly increased collagen deposi- following l-arginine administration. In ureteral obstruc-
tion, while the fibrotic response was greatly diminished tion and in salt-sensitive Dahl-Rapp rats, l-arginine ad-
in mice with a disrupted PAI-1 gene [40]. Using these ministration also reduced arterial pressure [9, 13]. In rats
disease markers in the present study, increases in glomer- with 5/6 nephrectomy, l-arginine supplementation nor-
ular production of 8.9-fold for TGF-b1, 15-fold for fibro- malized glomerular pressure [8]. However, in the ATS
nectin and 25-fold for PAI-1 were seen in untreated model of glomerulonephritis studied here, no blood pres-
diseased rats compared to normal controls. These sub- sure elevation was seen and, although l-arginine supple-
stantial differences between normal and untreated dis- mentation significantly increased arterial l-arginine lev-
eased rats provide a large therapeutic window that en- els it had no effect on systemic blood pressure and no
ables detection of small differences in drug efficacy. This effect on measures of NO. Therefore, we found no evi-
is demonstrated by the small, but clear and statistically dence that this therapy, in this model, acts through en-
significant additive therapeutic effect seen with l-argi- hanced systemic or glomerular NO production.
nine supplementation and low protein intake. It should As pointed out in a recent review article [42], there
be pointed out that the mRNA data shown in Figure 3 is still much to learn about the meaning of urinary and
were decreased in the dual therapy group compared to plasma NOx measurements. Even with this in mind, it
the single therapy groups, although this difference did appears likely that l-arginine supplementation reduces
not achieve statistical significance. This may simply be fibrotic disease by other mechanisms and not solely
due to the greater sample size (8 vs. 3) for the ELISA through enhanced vasodilatory NO production by endo-
measurements. On the other hand, we have obtained thelial cells. Taking the data presented here with other
similar results in a number of studies of this kind, sug- data in hypertensive diseases, it appears that l-arginine
gesting that the ELISA determinations are more sensi- acts through more than one pathway. If this were the case,
tive than the Northern data [5, 25]. Whatever the reason one would predict that if disease reduction with l-argi-
for these findings, we regard production of proteins as nine supplementation were quantified in a hypertensive
more relevant to fibrosis than expression of their model of renal fibrosis, as we have done here in ATS-
nephritis with small, if any hypertensive component [43],mRNAs.
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reduction of TGF-b overexpression might be greater caused by multiple pathological stimuli acting even
within one disease and that reduction of TGF-b overex-than the approximately 50% observed in this study.
The data on animals fed low protein confirm earlier pression is currently our best therapeutic target, these
data clearly point to therapeutic approaches involvingdemonstrations of the effects of 6% protein diet on re-
duction of fibrotic disease in this model [27]. In addition drug combinations. In this regard, the absence of additive
effects with enalapril and losartan combined [5] and theit quantitates the therapeutic effect, making comparison
with other therapies possible. Further, as discussed above, small additive effects seen here with l-arginine and low
protein and elsewhere with enalapril and low proteinthe data reveals a fascinating link between low protein
intake and reduction in renal NO synthesis. It is unlikely (Note added in proof) are of interest. Finally, these stud-
ies suggest that therapies that more directly target TGF-bthat the mechanism of this is the low l-arginine content
of low protein diet leading to decreased l-arginine as overexpression, such as antibodies, TGF-b receptor an-
tagonists or the natural TGF-b inhibitor, decorin, maysubstrate for cytotoxic NO production by iNOS because
glomerular NO production was substantially reduced in be required to halt the progression of renal fibrosis. It
should be noted that while there is considerable evidenceanimals given low protein and l-arginine as well as those
treated with low protein diet alone (Fig. 4D). that TGF-b overexpression currently appears to be our
best therapeutic target, reduction of this cytokine to sub-The present study suggests that the antifibrotic effect
of l-arginine supplementation is mediated through a re- normal levels may well be deleterious because of the
many beneficial roles of TGF-b in tissue repair.duction in TGF-b overexpression. l-arginine administra-
tion significantly reduced glomerular expression of TGF-b In conclusion, the present study shows that l-arginine
supplementation is therapeutic in ATS-glomerulone-and the matrix constituents fibronectin and PAI-1. Where
it has been investigated, reduction of pathological matrix phritis if started after the injury phase of disease. The
data suggest that in this disease model the mechanismdeposition has generally followed reduction in overex-
pression of TGF-b. One exception is a study where rats underlying this effect is not increased generation of NO
or reductions in systemic blood pressure as has beenwith unilateral ureteral obstruction were given drinking
water supplemented with 1% l-arginine [11]. The authors suggested by findings in hypertensive disease models.
suggest that direct effects of NO on collagen synthesis Therefore, l-arginine may act through multiple pathways
may be responsible for this unusual result [44, 45]. The to reduce fibrosis. Since l-arginine supplementation may
data presented here with ATS-nephritis give no sugges- increase tissue injury when iNOS is involved [25], only
tion of direct effects of l-arginine on matrix synthesis in further studies will reveal the true therapeutic potential
that matrix deposition and all other measures of disease of l-arginine supplementation in humans.
except proteinuria closely follow TGF-b.
The study presented here is the second in a series Note added in proof
designed to quantitate the efficacy of current and promis- I Peters H, Border WA, Noble NA: Angiotensin II blockade and
ing therapies in the ATS model of glomerulonephritis low-protein diet produce additive therapeutic effects in experimental
glomerulonephritis. Kidney Int (in press)where reduction of TGF-b overexpression is the target.
Although many publications using animal models and
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